Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa Patients (ENVISION)

NCTID	NCT06460844 (View at clinicaltrials.gov)
Description	A Phase 1, open-label, non-randomized, dose-escalation study, where approximately 9 eligible patients with retinitis pigmentosa will be enrolled sequentially in up to 3 dose cohorts of RTx-015. Enrolled patients will receive a single, unilateral intravitreal injection of RTx-015 in the study eye at Visit 3 (Day 0) and be followed for a total of 12 months. (Show More)
Indication	Retinitis Pigmentosa
Compound Name	RTx-015
Sponsor	Ray Therapeutics, Inc.
Funder Type	Industry
Status	Recruiting
Enrollment Count	9

Target Gene/Variant	Codon optimized ChR-3M
Therapy Type	Gene transfer
Therapy Route	In-vivo
Mechanism of Action	Overexpression of protective allele/gene
Route of Administration	Intravitreal
Drug Product Type	Viral vector
Target Tissue/Cell
Delivery System	Viral transduction
Vector Type	AAV.7m8
Editor Type
Dose 1	Undisclosed low dose
Dose 2	Undisclosed medium dose
Dose 3	Undisclosed high dose
Dose 4
Dose 5

No.of Trial Sites	2
Locations	United States

Has US IND	True
Recent Updates